A meta-analysis: the clinical value of PD-1 inhibitor or protein tyrosine kinase inhibitors in the treatment of advanced osteosarcoma

被引:4
|
作者
Shi, Binhao [1 ,2 ]
Chang, Junli [1 ,2 ]
Sun, Xingyuan [1 ,2 ]
Ma, Xiaoping [1 ,2 ]
Zhao, Peng [1 ,2 ]
Zhou, Chujie [1 ,2 ]
Wang, Yongjun [1 ,2 ]
Yang, Yanping [1 ,2 ]
机构
[1] Shanghai Univ Tradit Chinese Med, Longhua Hosp, Shanghai, Peoples R China
[2] Minist Educ, Key Lab Theory & Therapy Muscles & Bones, Shanghai, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2023年 / 13卷
关键词
immunotherapy; PD-1; inhibitors; protein tyrosinase inhibitors; advanced osteosarcoma; meta-analysis; DOUBLE-BLIND; PHASE-II; OPEN-LABEL; CABOZANTINIB; REGORAFENIB; TRIAL; IMMUNOTHERAPY; PEMBROLIZUMAB; CHEMOTHERAPY; METASTASIS;
D O I
10.3389/fonc.2023.1148735
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundsPD-1 inhibitors and TKIs have been used to treat advanced osteosarcoma, but there is still a lack of intuitive data for the comparison of their efficacy. We conducted a meta-analysis to evaluate their therapeutic benefits. MethodsA systematic methodological search of five primary electronic databases was performed. Studies with a randomized design of any type about PD-1 inhibitors or TKIs for the treatment of advanced osteosarcoma were included. The primary outcomes mainly included CBR, PFS, OS and ORR, The CR, PR, SD and AEs were the secondary outcomes. The survival period (months) of patients was taken as the main analysis data. Random-effects models were used for meta-analysis. ResultsEight immunocheckpoint inhibitors in 327 patients from 10 clinical trials were finally evaluated. For OS, TKIs [11.67 months (95% CI, 9.32-14.01)] show more obvious advantages than PD-1 inhibitors [6.37 months (95% CI, 3.96-8.78)]. For PFS, TKIs [4.79 months (95% CI, 3.33-6.24)] are longer than PD-1 inhibitors [1.46 months (95% CI, 1.23-1.69)]. Although there was no fatal event, attention should still be paid, especially during the combined application of PD-1 inhibitors with TKIs since their obvious AEs. ConclusionsThe findings of this study suggest that patients with advanced osteosarcoma, TKIs may be more beneficial than PD-1 inhibitors. TKIs combined with PD-1 inhibitors has a bright future in the treatment of advanced osteosarcoma, but we should always pay attention to the strong side effects.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] EFFICACY AND SAFETY OF PD-1/PD-L1 INHIBITORS USED IN THE TREATMENT OF PATIENTS WITH ADVANCED AND METASTATIC MELANOMA - A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
    Verma, J.
    Verma, D.
    Maria, A.
    VALUE IN HEALTH, 2020, 23 : S50 - S50
  • [42] EFFICACY AND SAFETY OF PD-1/PD-L1 INHIBITORS USED IN THE TREATMENT OF PATIENTS WITH ADVANCED AND METASTATIC MELANOMA - A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
    Oguzhan, G.
    Caliskan, Z.
    Kockaya, G.
    Kurnaz, M.
    Calli, C.
    Erturk, S. M.
    VALUE IN HEALTH, 2020, 23 : S50 - S50
  • [43] Clinical and molecular characteristics associated with the efficacy of PD-1/PD-L1 inhibitors for solid tumors: a meta-analysis
    Weng, Yi Ming
    Peng, Min
    Hu, Meng Xue
    Yao, Yi
    Song, Qi Bin
    ONCOTARGETS AND THERAPY, 2018, 11 : 7529 - 7542
  • [44] Comparative Impact of PD-1 and PD-L1 Inhibitors on Advanced Esophageal or Gastric/Gastroesophageal Junction Cancer Treatment: A Systematic Review and Meta-Analysis
    Oh, SuA
    Kim, Eunyoung
    Lee, Heeyoung
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (16)
  • [45] Safety of PD-L1 inhibitors versus PD-1 inhibitors in the treatment of lung cancer: a systematic review and network meta-analysis
    Ding, Jianqiao
    Liu, Zheyu
    Ning, Jing
    Sun, Nan
    EXPERT REVIEW OF ANTICANCER THERAPY, 2025, 25 (03) : 259 - 267
  • [46] Efficacy and safety of PD-1 inhibitors plus anti-angiogenesis tyrosine kinase inhibitors with or without transarterial chemo(embolization) for unresectable hepatocellular carcinoma: a meta-analysis
    Chen, Yue
    Jia, Luyao
    Li, Yu
    Cui, Wenhao
    Wang, Jukun
    Zhang, Chao
    Bian, Chunjing
    Luo, Tao
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [47] The Efficacy and Safety of PD-1/PD-L1 Inhibitors for Advanced Refractory Esophageal and GE Junction Cancer: A Meta-Analysis
    Li, Tian
    Zou, Yuntao
    Li, Yiting
    Friedenberg, Frank
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S346 - S346
  • [48] Efficacy and safety of PD-1 and PD-L1 inhibitors in advanced colorectal cancer: a meta-analysis of randomized controlled trials
    Wang, Zhenzi
    Liu, Yuan
    Wang, Kedi
    Ma, Liyan
    BMC GASTROENTEROLOGY, 2024, 24 (01)
  • [49] Effectiveness and safety of PD-1/PD-L1 inhibitors in advanced or recurrent endometrial cancer: a systematic review and meta-analysis
    Han, Songfei
    Guo, Cuishan
    Song, Zixuan
    Ouyang, Ling
    Wang, Yizi
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [50] The Efficacy and Safety of PD-1/PD-L1 Inhibitors in Combination with Conventional Therapies for Advanced Solid Tumors: A Meta-Analysis
    Nie, Run-Cong
    Zhao, Chong-Bang
    Xia, Xiao-Wei
    Luo, Ying-Shan
    Wu, Ting
    Zhou, Zhi-Wei
    Yuan, Shu-Qiang
    Wang, Yun
    Li, Yuan-Fang
    BIOMED RESEARCH INTERNATIONAL, 2020, 2020